<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="case-report" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Hematol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Hematology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Hematol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2813-3935</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/frhem.2026.1745884</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Case Report: two cases of idiopathic plasmacytic lymphadenopathy subtype of idiopathic multicentric Castleman disease with xanthelasma palpebrum from a Canadian center</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Andrew A. Y.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3085085/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Yin</surname><given-names>Vivian T.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Blanco</surname><given-names>Paula</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Trinder</surname><given-names>Mark</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Crawford</surname><given-names>Richard I.</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Henrie</surname><given-names>Ryan</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Parkin</surname><given-names>Stephen</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Khalil</surname><given-names>Nasreen</given-names></name>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Carruthers</surname><given-names>Mollie</given-names></name>
<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Lu</given-names></name>
<xref ref-type="aff" rid="aff8"><sup>8</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/512374/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname><given-names>Luke Y. C.</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff9"><sup>9</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1400276/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Biochemistry and Molecular Biology, Dalhousie University</institution>, <city>Halifax</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Ophthalmology &amp; Visual Sciences, University of British Columbia</institution>, <city>Vancouver</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Pathology and Laboratory Medicine, University of British Columbia</institution>, <city>Vancouver</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Dermatology and Skin Science, University of British Columbia</institution>, <city>Vancouver</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<aff id="aff5"><label>5</label><institution>Division of Hematology, University of British Columbia</institution>, <city>Vancouver</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<aff id="aff6"><label>6</label><institution>Division of Respirology, University of British Columbia</institution>, <city>Vancouver</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<aff id="aff7"><label>7</label><institution>Arthritis Research Canada</institution>, <city>Vancouver</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<aff id="aff8"><label>8</label><institution>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</institution>, <city>Beijing</city>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff9"><label>9</label><institution>Division of Hematology, Dalhousie University</institution>, <city>Halifax</city>, <state>BC</state>,&#xa0;<country country="ca">Canada</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Luke Y. C. Chen, <email xlink:href="mailto:lchen2@bccancer.bc.ca">lchen2@bccancer.bc.ca</email></corresp>
<fn fn-type="other" id="fn003">
<label>&#x2020;</label>
<p>ORCID: Lu Zhang, <uri xlink:href="https://orcid.org/0000-0002-0860-9625">orcid.org/0000-0002-0860-9625</uri>; Luke Y. C. Chen, <uri xlink:href="https://orcid.org/0000-0002-9551-2951">orcid.org/0000-0002-9551-2951</uri>; Vivian T. Yin, <uri xlink:href="https://orcid.org/0000-0001-8050-3588">orcid.org/0000-0001-8050-3588</uri>; Andrew A. Y. Chen, <uri xlink:href="https://orcid.org/0009-0006-8899-9059">orcid.org/0009-0006-8899-9059</uri></p></fn>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-23">
<day>23</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>5</volume>
<elocation-id>1745884</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>13</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Chen, Yin, Blanco, Trinder, Crawford, Henrie, Parkin, Khalil, Carruthers, Zhang and Chen.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Chen, Yin, Blanco, Trinder, Crawford, Henrie, Parkin, Khalil, Carruthers, Zhang and Chen</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-23">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Idiopathic plasmacytic lymphadenopathy is a newly recognized subtype of idiopathic multicentric Castleman disease (iMCD-IPL) and often mimics IgG4-related disease (IgG4-RD). We present two of the first cases of iMCD-IPL diagnosed in British Columbia, Canada. Both patients had normolipemic bilateral xanthelasma palpebrum, which has not previously been reported in iMCD-IPL.</p>
</sec>
<sec>
<title>Case report</title>
<p>Both patients were Asian women in the 5<sup>th</sup> decade who presented with anemia, inflammation, polyclonal hypergammaglobulinemia (PHGG), and xanthelasmas. IgG4-RD was initially suspected, but upon review of the lymph node histology and careful clinicopathological correlation, both were found to have iMCD-IPL with plasmacytic histology. Biopsies of the xanthelasmas revealed foamy macrophages consistent with common xanthelasmas. Both patients had partial clinical and biochemical response to siltuximab, but no change in xanthelasmas. We searched the literature and identified three cases of unicentric Castleman&#x2019;s disease (UCD) with xanthomas, systemic inflammation and PHGG. These three patients showed marked improvement in both systemic symptoms and xanthomas after resection of the UCD.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>We report two patients with normolipemic xanthelasmas and iMCD-IPL whose xanthelasmas did not regress with siltuximab. However, the regression of xanthomas in three cases of UCD from the literature suggest a potential pathophysiological association between Castleman disease and xanthomas.</p>
</sec>
</abstract>
<kwd-group>
<kwd>autoinflammation</kwd>
<kwd>Castleman</kwd>
<kwd>IgG4</kwd>
<kwd>immunohematology</kwd>
<kwd>polyclonal hypergammaglobulinemia</kwd>
<kwd>xanthelasmas</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. Luke Chen&#x2019;s research is supported by an unrestricted philanthropic donation from the Hsu &amp; Taylor family through the VGH &amp; UBC Hospital Foundation.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="26"/>
<page-count count="7"/>
<word-count count="2774"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Blood Cancer</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Idiopathic multicentric Castleman disease (iMCD) is a rare inflammatory lymphoproliferative disorder with protean manifestations (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). There are three distinct subtypes of iMCD: thrombocytopenia, anasarca, fever, renal dysfunction, organomegaly (iMCD-TAFRO), idiopathic plasmacytic lymphadenopathy (iMCD-IPL), and not otherwise specified (iMCD-NOS) (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>). The iMCD-IPL subtype is characterized by lymphadenopathy, systemic inflammation, and polyclonal hypergammaglobulinemia, often with elevated serum IgG4 levels and increased IgG4+ plasma cells, along with other Castleman-like histology in the lymph nodes (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Historically, patients with idiopathic plasmacytic lymphadenopathy (IPL) have diagnostic conundrums, particularly in the Western Hemisphere. Nearly all the extant literature is from East Asia, particularly Japan and China. The classification of IPL as a subtype of IgG4-related disease, Castleman disease, or a distinct entity has been a long- standing debate (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). However, over the past three years, consensus has emerged that IPL is indeed a third subtype of iMCD, and that these patients benefit from iMCD-directed therapy (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>With the recognition of IPL as a subtype of Castleman disease in North America, patients with previously undiagnosed syndromes of lymphadenopathy and inflammation are now being identified as iMCD-IPL. Here, we present two of the first cases of iMCD-IPL diagnosed in British Columbia, Canada. Both patients were young Asian women who had a &gt; 1 year history of lymphadenopathy and inflammation, both requiring review by Hematologists and Pathologists with expertise in Castleman disease to arrive at a clinicopathological diagnosis of iMCD-IPL. Strikingly, both patients had normolipemic xanthelasma palpebrum, which, to our knowledge, has not been previously reported in association with iMCD-IPL. Both patients provided written consent for publication.</p>
</sec>
<sec id="s2">
<title>Case 1</title>
<p>A 42-year-old Chinese woman presented with a 12-year history of chronic anemia, hypoalbuminemia, and inflammation, and a 5-year history of diffuse, asymptomatic, small-volume lymphadenopathy in the supraclavicular, thoracic, and intra-abdominal lymph nodes on computed tomography (CT) scan. She had undergone a left axillary lymph node biopsy 4-years prior to the current assessments which revealed non-specific reactive changes with polyclonal plasmacytosis. Her medical history was significant for an episode of cutaneous vasculitis, thought to be Henoch-Sch&#xf6;nlein purpura, at age 21, and lymphocytic interstitial pneumonitis (LIP) diagnosed on surgical lung biopsy at age 38; she had been treated with corticosteroids, mycophenolate mofetil, and rituximab with no appreciable improvement.</p>
<p>On physical examination, she was noted to have yellow plaques and papules on the medial and lateral aspects of both upper eyelids (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>). The lesions had been present for 10 years and had slowly increased in size and number over that time. She did not have palpable lymphadenopathy or organomegaly, and no other xanthomas were noted.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p><bold>(A)</bold> Case 1, demonstrating yellow lesions medially in both eyes. <bold>(B)</bold> Case 2, demonstrating medial and lateral yellow raised lesions in both eyelids.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="frhem-05-1745884-g001.tif">
<alt-text content-type="machine-generated">Two close-up images labeled A and B show a person's closed eyes. In image A, there are visible yellowish patches on the eyelids. In image B, the patches appear reduced or less prominent.</alt-text>
</graphic></fig>
<p>Positron emission tomography (PET) CT revealed lymphadenopathy up to 1.7 cm in the short axis, demonstrating mild <sup>18</sup>FDG avidity (SUV max 5.0) along with mild diffuse <sup>18</sup>FDG avidity in both the submandibular and parotid glands. Laboratory investigations (<xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>) revealed severe inflammation with elevated C-reactive protein (CRP) and polyclonal hypergammaglobulinemia consisting of elevated immunoglobulins, particularly IgG1. ANA was weakly positive 1.5 (ratio &lt;0.7), and extractable nuclear antibody was negative. The patient&#x2019;s serum lipid profile was normal. Her fasting lipid profile showed decreased HDL cholesterol 1.10 mmol/L (ref. &gt; 1.29) but was otherwise normal, fasting glucose was normal at 5.3 mmol/L, and her thyroid stimulating hormone (TSH), free T4, liver enzymes and INR were normal. She did not have any clinical submandibular or parotid symptoms or physical exam abnormalities so these organs were not biopsied.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Baseline laboratory values.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Parameter</th>
<th valign="middle" align="left">Case 1</th>
<th valign="middle" align="left">Case 2</th>
<th valign="middle" align="left">Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">WBC (giga/L)</td>
<td valign="middle" align="left">5.5</td>
<td valign="middle" align="left">6.2</td>
<td valign="middle" align="left">4.0-11.0</td>
</tr>
<tr>
<td valign="middle" align="left">Hemoglobin (g/L)</td>
<td valign="middle" align="left">93</td>
<td valign="middle" align="left">86</td>
<td valign="middle" align="left">&gt;115</td>
</tr>
<tr>
<td valign="middle" align="left">Platelets (Giga/L)</td>
<td valign="middle" align="left">377</td>
<td valign="middle" align="left">602</td>
<td valign="middle" align="left">150-400</td>
</tr>
<tr>
<td valign="middle" align="left">Albumin (g/L)</td>
<td valign="middle" align="left">29</td>
<td valign="middle" align="left">31.5</td>
<td valign="middle" align="left">32-50</td>
</tr>
<tr>
<td valign="middle" align="left">IgG (g/L)</td>
<td valign="middle" align="left">63.2</td>
<td valign="middle" align="left">33.3</td>
<td valign="middle" align="left">5.8-15.6</td>
</tr>
<tr>
<td valign="middle" align="left">IgA (g/L)</td>
<td valign="middle" align="left">9.86</td>
<td valign="middle" align="left">3.60</td>
<td valign="middle" align="left">0.70-4.00</td>
</tr>
<tr>
<td valign="middle" align="left">IgM (g/L)</td>
<td valign="middle" align="left">4.55</td>
<td valign="middle" align="left">0.91</td>
<td valign="middle" align="left">0.50-3.00</td>
</tr>
<tr>
<td valign="middle" align="left">IgG1 (g/L)</td>
<td valign="middle" align="left">&gt;40</td>
<td valign="middle" align="left">17.6</td>
<td valign="middle" align="left">2.80-8.00</td>
</tr>
<tr>
<td valign="middle" align="left">IgG4 (g/L)</td>
<td valign="middle" align="left">7.13</td>
<td valign="middle" align="left">4.96</td>
<td valign="middle" align="left">0.05-1.25</td>
</tr>
<tr>
<td valign="middle" align="left">CRP (mg/L)</td>
<td valign="middle" align="left">94.3</td>
<td valign="middle" align="left">161</td>
<td valign="middle" align="left">&lt;3.1</td>
</tr>
<tr>
<td valign="middle" align="left">Creatinine (&#xb5;mol/L)</td>
<td valign="middle" align="left">41</td>
<td valign="middle" align="left">43</td>
<td valign="middle" align="left">41-86</td>
</tr>
<tr>
<td valign="middle" align="left">C3 (g/L)</td>
<td valign="middle" align="left">0.98</td>
<td valign="middle" align="left">1.69</td>
<td valign="middle" align="left">0.68-1.68</td>
</tr>
<tr>
<td valign="middle" align="left">C4 (g/L)</td>
<td valign="middle" align="left">&lt;0.01</td>
<td valign="middle" align="left">0.38</td>
<td valign="middle" align="left">0.12-0.40</td>
</tr>
<tr>
<td valign="middle" align="left">HHV-8 viral load</td>
<td valign="middle" align="left">Negative</td>
<td valign="middle" align="left">Negative</td>
<td valign="middle" align="left"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>CRP, C-reactive protein; PHGG, polyclonal hypergammaglobulinemia; sCD25, soluble interleukin-2 receptor, &#x3b1;-chain; SPEP, serum protein electrophoresis. *Obtained after treatment initiation.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Upon review of her previous excisional lymph node biopsy as well as the lung specimen with associated lymph nodes, scattered reactive secondary lymphoid follicles with sheets of mature plasma cells expanding the interfollicular area were observed. Immunohistochemical stains for IgG4 and IgG showed greater than 100 IgG4-positive plasma cells per high-power field, with an IgG4:IgG ratio of less than 40%. No stromal fibrosis or storiform fibrosis was seen. With respect of iMCD histological features, there were few regressed germinal centers (1/3), negligible follicular dendritic cell predominance (0/3), moderately increased vascularity (2/3), many hyperplastic germinal centers (2/3), and very increased/&#x201d;sheet-like&#x201d; plasmacytosis (3/3) (<xref ref-type="bibr" rid="B7">7</xref>). (<xref ref-type="supplementary-material" rid="SF1"><bold>Supplementary Figure</bold></xref>) Immunohistochemistry for Latency-Associated Nuclear Antigen (LANA) in the lymph node, and serum human herpesvirus-8 (HHV-8) viral load were both negative. Importantly, these findings are not specific in isolation, but in the correct clinical context, as in this case, the patient was diagnosed with iMCD-IPL with IgG4 enriched plasmacytic histology.</p>
<p>She underwent a left upper eyelid biopsy, which revealed common xanthelasma palpebrum (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>). With the diagnosis of iMCD-IPL, she was started on siltuximab 11 mg/kg IV every three weeks with partial biochemical response. After 6 months of treatment, her hemoglobin was 107 g/L (from baseline 93 g/L), CRP was 16.5 mg/L (from baseline 94.3 mg/L), and IgG was 45.2 g/L (from baseline 63.2 g/L). Her xanthelasmas were unchanged.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Upper eyelid biopsies of xanthelasmas. <bold>(A, B)</bold> Case 1 and Case 2 low magnification, respectively. <bold>(C, D)</bold> Case 1 and Case 2 high magnification, respectively. Both cases show diffuse and perivascular aggregates of lipid-laden foamy histiocytes within the dermis. No increase in plasma cells. Immunohistochemistry for IgG4, S100, BRAF V600E and CD1a were negative.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="frhem-05-1745884-g002.tif">
<alt-text content-type="machine-generated">Microscopic images of tissue samples. Image A shows a cross-section of tissue with a thin, wavy layer. Image B displays a similar cross-section with thicker regions. Images C and D are close-ups showing detailed cellular structures with pink cytoplasm and dark purple nuclei, characteristic of stained pathology slides.</alt-text>
</graphic></fig>
</sec>
<sec id="s3">
<title>Case 2</title>
<p>A 40-year-old Filipino woman was referred for chronic lymphadenopathy, anemia, and inflammation. Two years prior to the current assessment, she had presented with right lower quadrant abdominal pain due to appendicitis. During laparoscopic appendectomy, she was incidentally found to have a 3.7 x 2.6 x 4.7 cm soft tissue mass in the left lower quadrant as well as additional lymphadenopathy in the small bowel mesentery and retroperitoneum.</p>
<p>On physical examination, she had yellow plaques and papules on the medial and lateral upper eyelids (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>) and small subcentimeter bilateral palpable inguinal lymph nodes. Laboratory investigations revealed anemia, inflammation (CRP 161 mg/L), and polyclonal hypergammaglobulinemia with elevated IgG4 4.96 g/L. She had a normal serum lipid profile, fasting glucose, TSH, free T4, liver enzymes and INR. A PET CT scan confirmed multiple <sup>18</sup>FDG avid lymph nodes in the left common iliac (3.2 x 3.9 cm, SUV-max 12.6), left psoas, and mesenteric regions. Laparoscopically obtained excisional biopsy of the pelvic retroperitoneal lymph node revealed increased plasma cells, with some areas of IgG4 positive plasma cells greater than 100 per high-power field IgG4-IgG ratio &gt; 40% (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref>). There was no stromal fibrosis or storiform fibrosis. Immunohistochemistry for Latency-Associated Nuclear Antigen (LANA) in the lymph node, and serum human herpesvirus-8 (HHV-8) viral load were both negative.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Pathology for Case 2 <bold>(A)</bold> Low-, medium-, and high-power images of hematoxylin and eosin stained left cervical lymph node tissue shows reactive follicular hyperplasia with some follicles displaying infiltration by the surrounding mantle cells, interfollicular areas composed of a mixture of small mature lymphocytes and plasma cells, and fibrous capsular thickening. <bold>(B)</bold> Immunohistochemistry shows the lymph node specimen has increased inter- and para-follicular IgG4-positive plasma cells that measure up to 100 cells per a high-power field (low and high-power images). <bold>(C)</bold> These IgG4-positive plasma cells focally account for more than 40% of the IgG-positive plasma cells (low and high-power images).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="frhem-05-1745884-g003.tif">
<alt-text content-type="machine-generated">Panel A shows hematoxylin and eosin-stained histological sections of tissue at low, medium, and high magnifications. Panel B displays low and medium magnification views of tissue stained with IgG4 antibodies, highlighting specific structures in brown against a blue background. Panel C shows similar staining as Panel B but with IgG antibodies, with differences in distribution and intensity.</alt-text>
</graphic></fig>
<p>Taken together, these findings were suspicious for iMCD-IPL; therefore, her lymph node biopsy was reviewed by a pathologist with expertise in Castleman disease. The lymph node showed negligible regressed germinal centers (0/3), negligible follicular dendritic cell predominance (0/3), moderately increased vascularity (2/3), mostly hyperplastic germinal centers (3/3), and moderately increased plasmacytosis (2/3) (<xref ref-type="bibr" rid="B7">7</xref>). Overall, this was considered consistent with the plasmacytic variant of Castleman disease (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref>). Eyelid biopsy revealed common xanthelasma palpebrum (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>). She was treated with siltuximab 11 mg/kg IV every three weeks with a partial response in her biochemical parameters: hemoglobin 127 g/L (from 89), CRP 13 mg/L (from 161) and IgG 25.6 g/L (from 33.3), but no change in the xanthelasmas.</p>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Clinicopathological correlation is crucial for the diagnosis of idiopathic multicentric Castleman disease (iMCD) as histological findings alone, such as regressed germinal centers, hypervascularity, and polyclonal plasmacytosis, are often non-specific. In both cases described here, the patients had pre-existing biopsy specimens that were initially read as reactive or non-diagnostic. For iMCD-IPL in particular, clinicopathological correlation is crucial, as there is substantial overlap with other entities, such as IgG4-RD and eosinophilic granulomatosis with polyangiitis; improved awareness of iMCD-IPL among clinicians and pathologists in the western hemisphere is needed. The cases described herein are two of the first cases of iMCD-IPL diagnosed in Canada.</p>
<p>The increased IgG4+ plasma cells and PHGG with elevated serum IgG4 raised suspicion for IgG4-related disease (IgG4-RD), but the anemia, markedly elevated CRP, and lack of other typical IgG4-RD manifestations (such as retroperitoneal fibrosis, lacrimal or salivary gland swelling, or pancreatic involvement) made this diagnosis unlikely (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). The lymph node histology was reviewed in the context of clinical and laboratory features suspicious for Castleman disease. Although lymphadenopathy in IgG4-related disease can often be non-specific, there were no other features present in the lymph such as stromal fibrosis or storiform fibrosis to suggest IgG4-RD. Thus, in combination with the other clinical and laboratory findings, a diagnosis of iMCD-IPL with plasmacytic histology was made in both cases, based on the diagnostic criteria proposed by Gao et&#xa0;al. (<xref ref-type="bibr" rid="B5">5</xref>):</p>
<list list-type="order">
<list-item>
<p>eligibility for the diagnostic criteria of iMCD-NOS.</p></list-item>
<list-item>
<p>elevated serum immunoglobulin G (IgG) level (&gt;17.4 g/L);</p></list-item>
<list-item>
<p>plasmacytic or mixed pathological subtypes2; and.</p></list-item>
<list-item>
<p>elevated platelet count (&gt;350 &#xd7; 109/L).</p></list-item>
</list>
<p>Xanthomas are cutaneous lesions that are histologically characterized by lipid-laden macrophages. Historically, xanthomas have been associated with hyperlipidemia, although recent studies have drawn this association into question (<xref ref-type="bibr" rid="B13">13</xref>). Xanthomas, particularly xanthelasma palpebrum, are important physical examination findings in patients suspected of having a hematological disorder, primarily due to their association with histiocyte disorders (<xref ref-type="bibr" rid="B14">14</xref>). Histiocytoses, particularly the group &#x201c;L&#x201d; (Langerhans Cell Histiocytosis and Erdheim-Chester disease), often present with xanthomas (<xref ref-type="bibr" rid="B15">15</xref>). In histiocyte disorders, xanthelasmas are histologically characterized by foamy histiocytes and Touton giant cells (<xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>We searched PubMed and interrogated the Castleman Disease Collaborative Network&#x2019;s ACCELERATE database for other cases of Castleman disease with xanthomas or xanthelasmas. No cases were found in the ACCELERATE database, which may reflect a lack of attention paid to this physical examination finding in CD patients (<xref ref-type="bibr" rid="B17">17</xref>). Three other cases of Castleman disease with xanthoma or xanthelasma have been identified in the literature and are summarized in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;1</bold></xref>.</p>
<p>The first was a 22-year old Afghan woman who presented with fatigue, weight loss, and generalized plane xanthomas of the peri-orbital regions, anterior neck, upper arms, and upper back (<xref ref-type="bibr" rid="B18">18</xref>). She had anemia, inflammation, thrombocytosis, alkaline phosphatase (ALP) 1700 IU/L (&lt;300 IU/L), and polyclonal hypergammaglobulinemia. Her HDL cholesterol level was slightly low 0.61 mmol/L (0.6-2.69) but the remainder of her lipid and complement levels were normal. Imaging revealed hepatomegaly, and liver biopsy showed sinusoid dilatation with peliotic (vascular) cysts and polyclonal plasmacytosis. She had a 6 cm retroperitoneal mass that was excised. The histology was consistent with the plasmacytic variant of Castleman disease. After excision of the lymph node mass, the patient gained 5 kg, her hepatomegaly resolved, the xanthomas regressed, and her PHGG improved (IgG 19.3 g/L). In retrospect, this appears to be unicentric Castleman disease with paraneoplastic systemic and hepatic inflammation and xanthelasmas. More recent studies have shown that UCD can cause systemic inflammation and paraneoplastic phenomena, such as pemphigus and bronchiolitis obliterans (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>).</p>
<p>The second describes a 23 year-old male who presented with hepatic sinusoidal dilatation and normolipemic periorbital plane xanthomas (<xref ref-type="bibr" rid="B21">21</xref>). He had severe wasting, celiac disease, polyclonal hypergammaglobulinemia, anemia, inflammation, elevated ALP 955 (&lt;160 IU/L), and hypoalbuminemia (24 g/L). Complement levels were not reported. The patient was found to have a large retroperitoneal mass which was completely resected. Histology showed hyaline vascular Castleman disease; his liver abnormalities, wasting, inflammation, and anemia resolved with resection, as did the plane xanthomas. Overall, this case seems consistent with UCD, which causes paraneoplastic inflammation and hepatic congestion.</p>
<p>The third was a 49-year old female patient with fever, fatigue, and hepatosplenomegaly with bilateral xanthelasma palpebrum (<xref ref-type="bibr" rid="B22">22</xref>). She was anemic, with marked polyclonal hypergammaglobulinemia and a normal serum lipid profile. Complements were normal. She had an 8.5 x 7 cm mass near the right ovary. Resection of the mass, which upon histology was UCD, resulted in improvement of xanthelasma lesions, anemia, inflammation, polyclonal hypergammaglobulinemia, and organomegaly.</p>
<p>Common xanthomas are traditionally thought to be related to hyperlipidemia and atherosclerosis. High serum levels of atherogenic low-density lipoproteins and upregulation of T-cells, macrophages, and inflammatory mediators are thought to contribute to their formation (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Subtle metabolic disturbance of lipid metabolism have been described in polyneuropathy, organomegaly, endocrinopathy, monoclonal paraprotein, skin changes (POEMS) syndrome, and Castleman disease (<xref ref-type="bibr" rid="B25">25</xref>). Although both patients presented here had normal serum lipid profiles, this does not exclude more subtle disturbances of lipid metabolism from their iMCD-IPL contributing. The biochemical mechanism of xanthelasmas in relation to iMCD-IPL is unclear and we seek to present these cases to prompt further investigation. Both patients were treated with prolonged release (PR), and it is possible controlled release (CR) dosage may result in xanthelasma remission, but this is speculative.</p>
<p>Patients with monoclonal proteins in necrobiotic xanthogranuloma (NXG) can develop xanthelasmas with normal serum lipid levels. The monoclonal immunoglobulin (Mlg) was IgG in 80% of presented cases, with myeloma diagnosed in 35% of these cases (<xref ref-type="bibr" rid="B26">26</xref>). While NXG is related to monoclonal proteins rather than polyclonal hypergammaglobulinemia, increased immunoglobulins in iMCD-IPL may also play a role. A key feature of iMCD-IPL is profound polyclonal hypergammaglobulinemia, which raises the question of whether these immune globulins play a role in xanthoma formation.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>These two cases of iMCD-IPL demonstrated the importance of clinicopathological correlations in CD. Both patients presented with xanthelasmas, which have not been previously reported in iMCD-IPL. The xanthelasmas in these two cases did not improve with siltuximab therapy. However, we also identified three cases of UCD associated with xanthomas, inflammation, and polyclonal hypergammaglobulinemia, all of which improved with resection of the UCD. This suggests a potential immune or inflammatory mechanism behind xanthomas in Castleman disease, which warrants further investigation.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by UBC Clinical Research Ethics Board. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>AC: Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. VTY:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. PB:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. MT: Investigation, Writing &#x2013; review &amp; editing. RC:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. RH:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. SP:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. NK:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. MC:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. LZ:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. LC:&#xa0;Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p></sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/frhem.2026.1745884/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/frhem.2026.1745884/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Presentation1.pptx" id="SF1" mimetype="application/vnd.openxmlformats-officedocument.presentationml.presentation"/>
<supplementary-material xlink:href="Table1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>L</given-names></name>
<name><surname>Fajgenbaum</surname> <given-names>DC</given-names></name>
</person-group>. 
<article-title>Castleman disease</article-title>. In: 
<person-group person-group-type="editor">
<name><surname>Stone</surname> <given-names>JH</given-names></name>
</person-group>, editor. <source>A clinician&#x2019;s pearls &amp; Myths in rheumatology</source>. 
<publisher-name>Springer International Publishing</publisher-name>, <publisher-loc>Cham</publisher-loc> (<year>2023</year>). p. <page-range>727&#x2013;35</page-range>.
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>LYC</given-names></name>
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<name><surname>Fajgenbaum</surname> <given-names>DC</given-names></name>
</person-group>. 
<article-title>Expert perspective: diagnosis and treatment of castleman disease</article-title>. <source>Arthritis Rheumatol</source>. (<year>2025</year>) <volume>78</volume>:<page-range>12&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.43269</pub-id>, PMID: <pub-id pub-id-type="pmid">40457814</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Otsuka</surname> <given-names>M</given-names></name>
<name><surname>Koga</surname> <given-names>T</given-names></name>
<name><surname>Sumiyoshi</surname> <given-names>R</given-names></name>
<name><surname>Fukui</surname> <given-names>S</given-names></name>
<name><surname>Kaneko</surname> <given-names>Y</given-names></name>
<name><surname>Shimizu</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Exploring the clinical diversity of castleman disease and TAFRO syndrome: A Japanese multicenter study on lymph node distribution patterns</article-title>. <source>Am J Hematol</source>. (<year>2025</year>) <volume>100</volume>:<page-range>592&#x2013;605</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ajh.27612</pub-id>, PMID: <pub-id pub-id-type="pmid">39865257</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nishikori</surname> <given-names>A</given-names></name>
<name><surname>Nishimura</surname> <given-names>MF</given-names></name>
<name><surname>Fajgenbaum</surname> <given-names>DC</given-names></name>
<name><surname>Nishimura</surname> <given-names>Y</given-names></name>
<name><surname>Maehama</surname> <given-names>K</given-names></name>
<name><surname>Haratake</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease</article-title>. <source>J Clin Pathol</source>. (<year>2024</year>) <volume>79</volume>:<page-range>43&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jcp-2023-209280</pub-id>, PMID: <pub-id pub-id-type="pmid">38378248</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname> <given-names>YH</given-names></name>
<name><surname>Liu</surname> <given-names>YT</given-names></name>
<name><surname>Zhang</surname> <given-names>MY</given-names></name>
<name><surname>Li</surname> <given-names>SY</given-names></name>
<name><surname>Fajgenbaum</surname> <given-names>DC</given-names></name>
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival</article-title>. <source>Br J Haematol</source>. (<year>2024</year>) <volume>204</volume>:<page-range>1830&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bjh.19334</pub-id>, PMID: <pub-id pub-id-type="pmid">38356434</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rowe</surname> <given-names>S</given-names></name>
<name><surname>Goubran</surname> <given-names>M</given-names></name>
<name><surname>Sarmiento Bustamante</surname> <given-names>M</given-names></name>
<name><surname>Shyamsundar</surname> <given-names>S</given-names></name>
<name><surname>Austin</surname> <given-names>B</given-names></name>
<name><surname>McNicholas</surname> <given-names>K</given-names></name>
<etal/>
</person-group>. 
<article-title>Ferritin, C-reactive protein, and soluble CD25 distinguish TAFRO from HLH</article-title>. <source>Am J Hematol</source>. (<year>2025</year>) <volume>100</volume>:<page-range>2421&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/ajh.70081</pub-id>, PMID: <pub-id pub-id-type="pmid">41001767</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fajgenbaum</surname> <given-names>DC</given-names></name>
<name><surname>Uldrick</surname> <given-names>TS</given-names></name>
<name><surname>Bagg</surname> <given-names>A</given-names></name>
<name><surname>Frank</surname> <given-names>D</given-names></name>
<name><surname>Wu</surname> <given-names>D</given-names></name>
<name><surname>Srkalovic</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease</article-title>. <source>Blood</source>. (<year>2017</year>) <volume>129</volume>:<page-range>1646&#x2013;57</page-range>., PMID: <pub-id pub-id-type="pmid">28087540</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Takeuchi</surname> <given-names>K</given-names></name>
</person-group>. 
<article-title>Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980</article-title>. <source>J Clin Exp Hematop</source>. (<year>2022</year>) <volume>62</volume>:<fpage>79</fpage>&#x2013;<lpage>84</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3960/jslrt.22011</pub-id>, PMID: <pub-id pub-id-type="pmid">35768240</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>LYC</given-names></name>
</person-group>. 
<article-title>IgG4-related disease for the hematologist</article-title>. <source>Hematol Am Soc Hematol Educ Program</source>. (<year>2024</year>) <volume>2024</volume>:<fpage>594</fpage>&#x2013;<lpage>603</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/hematology.2024000584</pub-id>, PMID: <pub-id pub-id-type="pmid">39644037</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nishikori</surname> <given-names>A</given-names></name>
<name><surname>Nishimura</surname> <given-names>MF</given-names></name>
<name><surname>Nishimura</surname> <given-names>Y</given-names></name>
<name><surname>Otsuka</surname> <given-names>F</given-names></name>
<name><surname>Maehama</surname> <given-names>K</given-names></name>
<name><surname>Ohsawa</surname> <given-names>K</given-names></name>
<etal/>
</person-group>. 
<article-title>Idiopathic plasmacytic lymphadenopathy forms an independent subtype of idiopathic multicentric castleman disease</article-title>. <source>Int J Mol Sci</source>. (<year>2022</year>) <volume>23</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms231810301</pub-id>, PMID: <pub-id pub-id-type="pmid">36142213</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname> <given-names>LYC</given-names></name>
<name><surname>Mattman</surname> <given-names>A</given-names></name>
<name><surname>Seidman</surname> <given-names>MA</given-names></name>
<name><surname>Carruthers</surname> <given-names>MN</given-names></name>
</person-group>. 
<article-title>IgG4-related disease: what a hematologist needs to know</article-title>. <source>Hematologica</source>. (<year>2019</year>) <volume>104</volume>:<page-range>444&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3324/haematol.2018.205526</pub-id>, PMID: <pub-id pub-id-type="pmid">30705099</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>EJ</given-names></name>
<name><surname>Cheng</surname> <given-names>CV</given-names></name>
<name><surname>Mattman</surname> <given-names>A</given-names></name>
<name><surname>Chen</surname> <given-names>LYC</given-names></name>
</person-group>. 
<article-title>Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>8</volume>:<page-range>e365&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2352-3026(21)00056-9</pub-id>, PMID: <pub-id pub-id-type="pmid">33894171</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lustig-Barzelay</surname> <given-names>Y</given-names></name>
<name><surname>Kapelushnik</surname> <given-names>N</given-names></name>
<name><surname>Goldshtein</surname> <given-names>I</given-names></name>
<name><surname>Leshno</surname> <given-names>A</given-names></name>
<name><surname>Segev</surname> <given-names>S</given-names></name>
<name><surname>Ben-Simon</surname> <given-names>GJ</given-names></name>
<etal/>
</person-group>. 
<article-title>Association between xanthelasma palpebrarum with cardiovascular risk and dyslipidemia: A case control study</article-title>. <source>Ophthalmology</source>. (<year>2025</year>) <volume>132</volume>:<page-range>164&#x2013;9</page-range>.
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McClain</surname> <given-names>KL</given-names></name>
<name><surname>Bigenwald</surname> <given-names>C</given-names></name>
<name><surname>Collin</surname> <given-names>M</given-names></name>
<name><surname>Haroche</surname> <given-names>J</given-names></name>
<name><surname>Marsh</surname> <given-names>RA</given-names></name>
<name><surname>Merad</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Histiocytic disorders</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2021</year>) <volume>7</volume>:<fpage>73</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41572-021-00307-9</pub-id>, PMID: <pub-id pub-id-type="pmid">34620874</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Emile</surname> <given-names>JF</given-names></name>
<name><surname>Cohen-Aubart</surname> <given-names>F</given-names></name>
<name><surname>Collin</surname> <given-names>M</given-names></name>
<name><surname>Fraitag</surname> <given-names>S</given-names></name>
<name><surname>Idbaih</surname> <given-names>A</given-names></name>
<name><surname>Abdel-Wahab</surname> <given-names>O</given-names></name>
<etal/>
</person-group>. 
<article-title>Histiocytosis</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>398</volume>:<page-range>157&#x2013;70</page-range>.
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Huynh</surname> <given-names>A</given-names></name>
<name><surname>Pryma</surname> <given-names>C</given-names></name>
<name><surname>McPhaden</surname> <given-names>H</given-names></name>
<name><surname>Yared</surname> <given-names>K-C</given-names></name>
<name><surname>Zhang</surname> <given-names>Y</given-names></name>
<name><surname>Beadon</surname> <given-names>K</given-names></name>
<etal/>
</person-group>. 
<article-title>A 52-year-old woman with dysarthria, ataxia, xanthelasmas, and miliary pulmonary nodules</article-title>. <source>Chest</source>. (<year>2024</year>) <volume>165</volume>:<fpage>e95</fpage>&#x2013;<lpage>e100</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.chest.2023.10.034</pub-id>, PMID: <pub-id pub-id-type="pmid">38599764</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pierson</surname> <given-names>SK</given-names></name>
<name><surname>Khor</surname> <given-names>JS</given-names></name>
<name><surname>Ziglar</surname> <given-names>J</given-names></name>
<name><surname>Liu</surname> <given-names>A</given-names></name>
<name><surname>Floess</surname> <given-names>K</given-names></name>
<name><surname>NaPier</surname> <given-names>E</given-names></name>
<etal/>
</person-group>. 
<article-title>ACCELERATE: A patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder</article-title>. <source>Cell Rep Med</source>. (<year>2020</year>) <volume>1</volume>:<fpage>100158</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100158</pub-id>, PMID: <pub-id pub-id-type="pmid">33377129</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sherman</surname> <given-names>D</given-names></name>
<name><surname>Ramsay</surname> <given-names>B</given-names></name>
<name><surname>Theodorou</surname> <given-names>N</given-names></name>
<name><surname>Woodrow</surname> <given-names>D</given-names></name>
<name><surname>Paradinas</surname> <given-names>F</given-names></name>
<name><surname>Cream</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Reversible plane xanthoma, vasculitis, and peliosis hepatis in giant lymph node hyperplasia (Castleman&#x2019;s disease): A case report and review of the cutaneous manifestations of giant lymph node hyperplasia</article-title>. <source>J Am Acad Dermatol</source>. (<year>1992</year>) <volume>26</volume>:<page-range>105&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0190-9622(92)70016-9</pub-id>, PMID: <pub-id pub-id-type="pmid">1732315</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>YT</given-names></name>
<name><surname>Zhen</surname> <given-names>JF</given-names></name>
<name><surname>Gao</surname> <given-names>YH</given-names></name>
<name><surname>Li</surname> <given-names>SY</given-names></name>
<name><surname>Dang</surname> <given-names>Y</given-names></name>
<name><surname>Xu</surname> <given-names>HY</given-names></name>
<etal/>
</person-group>. 
<article-title>Unicentric Castleman disease complicated with bronchiolitis obliterans: A single-center retrospective study from China</article-title>. <source>Br J Haematol</source>. (<year>2025</year>) <volume>206</volume>:<page-range>1129&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bjh.19966</pub-id>, PMID: <pub-id pub-id-type="pmid">40210608</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dieudonne</surname> <given-names>Y</given-names></name>
<name><surname>Silvestrini</surname> <given-names>MA</given-names></name>
<name><surname>Dossier</surname> <given-names>A</given-names></name>
<name><surname>Meignin</surname> <given-names>V</given-names></name>
<name><surname>Jouenne</surname> <given-names>F</given-names></name>
<name><surname>Mahevas</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Paraneoplastic pemphigus uncovers distinct clinical and biological phenotypes of western unicentric Castleman disease</article-title>. <source>Br J Haematol</source>. (<year>2023</year>) <volume>202</volume>:<page-range>267&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/bjh.18847</pub-id>, PMID: <pub-id pub-id-type="pmid">37221131</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Curciarello</surname> <given-names>J</given-names></name>
<name><surname>Castelletto</surname> <given-names>R</given-names></name>
<name><surname>Barbero</surname> <given-names>R</given-names></name>
<name><surname>Belloni</surname> <given-names>P</given-names></name>
<name><surname>Gelemur</surname> <given-names>M</given-names></name>
<name><surname>Castelletto</surname> <given-names>E</given-names></name>
<etal/>
</person-group>. 
<article-title>Hepatic sinusoidal dilatation associated to giant lymph node hyperplasia (Castleman&#x2019;s): a new case in a patient with periorbital xanthelasmas and history of celiac disease</article-title>. <source>J Clin Gastroenterol</source>. (<year>1998</year>) <volume>27</volume>:<page-range>76&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/00004836-199807000-00017</pub-id>, PMID: <pub-id pub-id-type="pmid">9706777</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Floudas</surname> <given-names>C</given-names></name>
<name><surname>Yiakoumis</surname> <given-names>X</given-names></name>
<name><surname>Tsironi</surname> <given-names>M</given-names></name>
<name><surname>Aessopos</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Reversible normolipemic xanthelasma palpebrarum associated with inflammation in Castleman&#x2019;s disease</article-title>. <source>Eur J Inflammation</source>. (<year>2008</year>) <volume>6</volume>:<page-range>95&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/1721727X0800600208</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname> <given-names>HC</given-names></name>
<name><surname>Sung</surname> <given-names>CW</given-names></name>
<name><surname>Lin</surname> <given-names>MH</given-names></name>
</person-group>. 
<article-title>Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: A systematic review and meta-analysis</article-title>. <source>J Am Acad Dermatol</source>. (<year>2020</year>) <volume>82</volume>:<fpage>596</fpage>&#x2013;<lpage>605</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaad.2019.08.082</pub-id>, PMID: <pub-id pub-id-type="pmid">31499151</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Govorkova</surname> <given-names>MS</given-names></name>
<name><surname>Milman</surname> <given-names>T</given-names></name>
<name><surname>Ying</surname> <given-names>GS</given-names></name>
<name><surname>Pan</surname> <given-names>W</given-names></name>
<name><surname>Silkiss</surname> <given-names>RZ</given-names></name>
</person-group>. 
<article-title>Inflammatory mediators in xanthelasma palpebrarum: histopathologic and immunohistochemical study</article-title>. <source>Ophthalmic Plast Reconstr Surg</source>. (<year>2018</year>) <volume>34</volume>:<page-range>225&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/IOP.0000000000000921</pub-id>, PMID: <pub-id pub-id-type="pmid">28481769</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>H</given-names></name>
<name><surname>Gao</surname> <given-names>XM</given-names></name>
<name><surname>Cao</surname> <given-names>XX</given-names></name>
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<name><surname>Zhou</surname> <given-names>DB</given-names></name>
<name><surname>Li</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Revealing serum lipidomic characteristics and potential lipid biomarkers in patients with POEMS syndrome</article-title>. <source>J Cell Mol Med</source>. (<year>2021</year>) <volume>25</volume>:<page-range>4307&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jcmm.16486</pub-id>, PMID: <pub-id pub-id-type="pmid">33779058</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Szalat</surname> <given-names>R</given-names></name>
<name><surname>Arnulf</surname> <given-names>B</given-names></name>
<name><surname>Karlin</surname> <given-names>L</given-names></name>
<name><surname>Rybojad</surname> <given-names>M</given-names></name>
<name><surname>Asli</surname> <given-names>B</given-names></name>
<name><surname>Malphettes</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy</article-title>. <source>Blood J Am Soc Hematol</source>. (<year>2011</year>) <volume>118</volume>:<page-range>3777&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2011-05-356907</pub-id>, PMID: <pub-id pub-id-type="pmid">21757618</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/887303">Prashant Ramesh Tembhare</ext-link>, Research and Education in Cancer (ACTREC), India</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3135419">Dorottya Laczko</ext-link>, University of Pennsylvania, United States</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3319019">Ann Thomas</ext-link>, MVR Cancer Centre and Research Institute, India</p></fn>
</fn-group>
</back>
</article>